Bianco James A. 4

4 · Kintara Therapeutics, Inc. · Filed Oct 22, 2024

Form 4

Period: 2024-10-18

DirectorChief Executive Officer

Transactions

Award
Common Stock
2024-10-18+2,323,307→ 2,323,307 total
Award
Options (Right to Buy)
2024-10-18+71,560→ 71,560 total
Exercise: $3.69Exp: 2033-04-07→ Common Stock (71,560 underlying)
Award
Options (Right to Buy)
2024-10-18+357,800→ 357,800 total
Exercise: $3.69From: 2024-10-18Exp: 2031-07-01→ Common Stock (357,800 underlying)
Award
Options (Right to Buy)
2024-10-18+191,280→ 191,280 total
Exercise: $4.14Exp: 2034-02-28→ Common Stock (191,280 underlying)

Footnotes (3)

[F1]Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."
[F2]One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023.
[F3]One-third of the stock options become exercisable on the first, second and third anniversary of February 28, 2024.

Documents

1 file